Innoviva, Inc. Common Stock
INVAInnoviva, Inc. is a biotechnology company focused on the development and commercialization of respiratory and other specialty healthcare products. It primarily licenses its portfolio of pharmaceutical products and intellectual property to partner companies, with a strong emphasis on inhaled therapeutics for conditions like asthma and COPD. The company leverages its expertise in respiratory medicine to generate royalty revenue and support its strategic growth initiatives.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 30, 2015 | $0.25 | 2015-09-08 | 2015-09-10 |
| June 30, 2015 | $0.25 | 2015-06-10 | 2015-06-12 |
| March 31, 2015 | $0.25 | 2015-03-10 | 2015-03-12 |
| December 23, 2014 | $0.25 | 2014-11-21 | 2014-11-25 |
| September 18, 2014 | $0.25 | 2014-08-26 | 2014-08-28 |
Dividends Summary
- Innoviva, Inc. Common Stock has issued 5 dividend payments over the past 1 years
- The most recent dividend was paid 3722 days ago, on September 30, 2015
- The highest dividend payed out to investors during this period was $0.25 per share
- The average dividend paid during this period was $0.25 per share.
Company News
Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.
Basilea Pharmaceutica Ltd has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States.
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We ...
High-quality stocks can do well when prices are rising or falling. Here’s why.
J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.
